Supreme Court Raises Threshold for Skinny Label Inducement Claims
Pharmaceutical brand and generic company counsel must revise patent litigation risk assessments after the Supreme Court imposed a higher bar for proving skinny label inducement of patented drug uses.
The U.S. Supreme Court issued a ruling tightening the standard for proving patent inducement claims tied to generic drug skinny labels, which only include FDA-approved indications that do not infringe a brand’s listed patents. The Court held that patentees must demonstrate a generic label would actively encourage infringement of the specific patented indication, rather than merely showing the generic product could be used for that purpose. Brand pharmaceutical companies face higher hurdles to block generic entry via inducement claims, while generic manufacturers gain additional protection against post-approval patent suits. In-house counsel should review pending and future patent litigation strategies, update risk models for drug lifecycle management, and assess existing skinny label approval applications for compliance with the new standard.